Order Article Reprints

Cimellaro A, Addesi D, Cavallo M, Spagnolo F, Suraci E, Cordaro R, Spinelli I, Passafaro F, Colosimo M, Pintaudi M, et al. Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study. Biomedicines. 2022; 10(12):3135. https://doi.org/10.3390/biomedicines10123135

Cimellaro, Antonio, Desirée Addesi, Michela Cavallo, Francesco Spagnolo, Edoardo Suraci, Raffaella Cordaro, Ines Spinelli, Francesco Passafaro, Manuela Colosimo, Medea Pintaudi, and et al. 2022. "Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study" Biomedicines 10, no. 12: 3135. https://doi.org/10.3390/biomedicines10123135

Cimellaro, A., Addesi, D., Cavallo, M., Spagnolo, F., Suraci, E., Cordaro, R., Spinelli, I., Passafaro, F., Colosimo, M., Pintaudi, M., Pintaudi, C., & on behalf of the CATAnzaro LOng COVID (CATALOCO) Study Group. (2022). Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study. Biomedicines, 10(12), 3135. https://doi.org/10.3390/biomedicines10123135